A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02082899|
Recruitment Status : Completed
First Posted : March 10, 2014
Last Update Posted : July 11, 2014
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Allergic Conjunctivitis||Drug: Active Comparator EBI-005 5 mg/mL Drug: Placebo Comparator||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||150 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||A Single Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel, Group Study to Assess the Efficacy of EBI-005 Topical Ophthalmic Solution for the Treatment of Moderate to Severe Allergic Conjunctivitis Using an Environmental Exposure Chamber (EEC) Model and Conjunctival Allergen Provocation Test (CAPT) Model|
|Study Start Date :||February 2014|
|Actual Primary Completion Date :||June 2014|
|Actual Study Completion Date :||July 2014|
Active Comparator: Active Comparator EBI-005 5 mg/mL
Administered 3 times per day
Drug: Active Comparator EBI-005 5 mg/mL
Placebo Comparator: Placebo Comparator
Administered 3 times per day
Drug: Placebo Comparator
- Ocular itching in EEC arm at a specific visit comparing EBI-005 vs vehicle [ Time Frame: 17 days ]
- Evaluation of Adverse Events. [ Time Frame: up to 45 days ]Frequency, severity and relationship to study medication of all Adverse Events occurring during the study.
- Evaluation of antibodies to EBI-005. [ Time Frame: up to 45 days ]Number and percent of subjects who develop drug antibodies over time
- Evaluation of ocular changes [ Time Frame: up to 45 days ]Changes in ophthalmic examinations over time.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Provide written informed consent prior to any study-related procedures.
- Be 18 years of age or older.
- Have at least a 2 year history of moderate to severe allergic conjunctivitis.
- Have a positive skin prick test to ragweed within the past 12 months of Screening (Visit 1A).
- Have a score of ≥ 2 for staff-assessed ocular redness in at least one region (nasal or temporal) in each eye and ≥ 2 for subject-assessed ocular itching within the 3.5-hour period of allergen exposure in the EEC at Visit 1B.
- Have required more than one anti-allergy pharmaceutical treatments in the past 2 years to treat ocular symptoms (including oral, topical, nasal treatments).
- Be able to self-administer topical ophthalmic drops.
- Avoid any topical or systemic ocular medications during the entire study period.
- Are willing and able to follow instructions and can be present for the required study visits for the duration of the study.
- Are female and of childbearing potential and unwilling to remain abstinent through 30 days following the last dose of study drug or not willing to use acceptable birth control methods.
- Have previously used an IL-1 blocker (e.g., Anakinra, Rilonacept, or Ilaris).
- Have a known contraindication or hypersensitivities to Anakinra (Kineret®) or any therapeutic agent targeted to IL-1 or any component of study drug formulation.
- Current participation in another clinical study involving an experimental treatment or participation in such a study within 30 days prior to study entry.
- Require concomitant use of TNF-blocking agents (e.g., Etanercept, Adalimumab, Infliximab).
- Have a history of glaucoma or intraocular pressure (IOP) > 25 mmHg at the Visit 1A (Medical Screening) or a history of elevated IOP within the past year.
- Have had ocular surgery including laser procedures within the past 12 months of Visit 1A (Medical Screening).
- Have had contact lens wear within 4 weeks prior to Visit 1A (Medical Screening) or unwilling to discontinue wear during the study period
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02082899
|Mississauga, Ontario, Canada, L4W 1A2|
|Study Director:||Michael Goldstein, MD||Eleven Biotherapeutics|
|Responsible Party:||Eleven Biotherapeutics|
|Other Study ID Numbers:||
|First Posted:||March 10, 2014 Key Record Dates|
|Last Update Posted:||July 11, 2014|
|Last Verified:||July 2014|
Interleukin 1 Receptor Inhibitor
Environmental Exposure Chamber
Conjunctival Allergen Provocation Test
Immune System Diseases